Is APYX or BEAT more profitable?

HeartBeam has a net margin of 0.00% compared to Apyx Medical's net margin of -14.78%. Apyx Medical's return on equity of -76.60% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets Apyx Medical -14.78% -76.60% -13.91% HeartBeam N/A -686.78% -348.65%

Which has higher earnings & valuation, CNXU or BEAT?

Conexeu Sciences is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Conexeu Sciences N/A N/A -$3.92M -$0.40 N/A HeartBeam N/A N/A -$21.01M -$0.51 N/A

Is CNXU or BEAT more profitable?

Conexeu Sciences' return on equity of -200.20% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets Conexeu Sciences N/A -200.20% -177.26% HeartBeam N/A -686.78% -348.65%

Does the media prefer CNXU or BEAT?

In the previous week, Conexeu Sciences and Conexeu Sciences both had 2 articles in the media. Conexeu Sciences' average media sentiment score of 0.48 beat HeartBeam's score of 0.31 indicating that Conexeu Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Conexeu Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HeartBeam 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend KEQU or BEAT?

HeartBeam has a consensus price target of $4.00, indicating a potential upside of 895.52%. Given HeartBeam's stronger consensus rating and higher probable upside, analysts clearly believe HeartBeam is more favorable than Kewaunee Scientific. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kewaunee Scientific 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 HeartBeam 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.56

Does the media favor KEQU or BEAT?

In the previous week, Kewaunee Scientific and Kewaunee Scientific both had 2 articles in the media. Kewaunee Scientific's average media sentiment score of 0.86 beat HeartBeam's score of 0.31 indicating that Kewaunee Scientific is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kewaunee Scientific 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HeartBeam 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BEAT or HYPR more profitable?

HeartBeam has a net margin of 0.00% compared to Hyperfine's net margin of -210.75%. Hyperfine's return on equity of -97.88% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets HeartBeam N/A -686.78% -348.65% Hyperfine -210.75% -97.88% -61.81%

Does the media favor BEAT or HYPR?

In the previous week, Hyperfine had 9 more articles in the media than HeartBeam. MarketBeat recorded 11 mentions for Hyperfine and 2 mentions for HeartBeam. Hyperfine's average media sentiment score of 0.50 beat HeartBeam's score of 0.31 indicating that Hyperfine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HeartBeam 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hyperfine 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BEAT or ECOR more profitable?

HeartBeam has a net margin of 0.00% compared to electroCore's net margin of -39.96%. electroCore's return on equity of 0.00% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets HeartBeam N/A -686.78% -348.65% electroCore -39.96% N/A -81.35%

Does the media refer more to BEAT or ECOR?

In the previous week, HeartBeam and HeartBeam both had 2 articles in the media. electroCore's average media sentiment score of 0.60 beat HeartBeam's score of 0.31 indicating that electroCore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HeartBeam 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral electroCore 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

HeartBeam (BEAT) Competitors

$0.38 -0.02 (-4.18%)

As of 12:05 PM Eastern

Compare

BEAT vs. APYX, CNXU, KEQU, HYPR, and ECOR

Should you buy HeartBeam stock or one of its competitors? HeartBeam's main competitors and comparable companies include Apyx Medical (APYX), Conexeu Sciences (CNXU), Kewaunee Scientific (KEQU), Hyperfine (HYPR), and electroCore (ECOR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does HeartBeam compare to Apyx Medical?

Apyx Medical (NASDAQ:APYX) and HeartBeam (NASDAQ:BEAT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Apyx Medical has higher revenue and earnings than HeartBeam. Apyx Medical is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apyx Medical	$52.84M	2.07	-$11.21M	-$0.20	N/A
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A

Apyx Medical presently has a consensus target price of $6.50, suggesting a potential upside of 150.00%. HeartBeam has a consensus target price of $4.00, suggesting a potential upside of 895.52%. Given HeartBeam's higher possible upside, analysts plainly believe HeartBeam is more favorable than Apyx Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apyx Medical	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
HeartBeam	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Apyx Medical has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, HeartBeam has a beta of -0.76, meaning that its stock price is 176% less volatile than the broader market.

55.3% of Apyx Medical shares are held by institutional investors. Comparatively, 7.8% of HeartBeam shares are held by institutional investors. 15.9% of Apyx Medical shares are held by company insiders. Comparatively, 18.0% of HeartBeam shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

HeartBeam has a net margin of 0.00% compared to Apyx Medical's net margin of -14.78%. Apyx Medical's return on equity of -76.60% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apyx Medical	-14.78%	-76.60%	-13.91%
HeartBeam	N/A	-686.78%	-348.65%

In the previous week, HeartBeam had 1 more articles in the media than Apyx Medical. MarketBeat recorded 2 mentions for HeartBeam and 1 mentions for Apyx Medical. Apyx Medical's average media sentiment score of 1.79 beat HeartBeam's score of 0.31 indicating that Apyx Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Apyx Medical	Very Positive
HeartBeam	Neutral

Summary

Apyx Medical beats HeartBeam on 10 of the 14 factors compared between the two stocks.

How does HeartBeam compare to Conexeu Sciences?

Conexeu Sciences (NASDAQ:CNXU) and HeartBeam (NASDAQ:BEAT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

7.8% of HeartBeam shares are held by institutional investors. 18.0% of HeartBeam shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Conexeu Sciences presently has a consensus target price of $20.00, suggesting a potential upside of 504.23%. HeartBeam has a consensus target price of $4.00, suggesting a potential upside of 895.52%. Given HeartBeam's stronger consensus rating and higher probable upside, analysts clearly believe HeartBeam is more favorable than Conexeu Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Conexeu Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
HeartBeam	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

In the previous week, Conexeu Sciences and Conexeu Sciences both had 2 articles in the media. Conexeu Sciences' average media sentiment score of 0.48 beat HeartBeam's score of 0.31 indicating that Conexeu Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Conexeu Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HeartBeam	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Conexeu Sciences' return on equity of -200.20% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Conexeu Sciences	N/A	-200.20%	-177.26%
HeartBeam	N/A	-686.78%	-348.65%

Conexeu Sciences is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Conexeu Sciences	N/A	N/A	-$3.92M	-$0.40	N/A
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A

Summary

HeartBeam beats Conexeu Sciences on 6 of the 11 factors compared between the two stocks.

How does HeartBeam compare to Kewaunee Scientific?

Kewaunee Scientific (NASDAQ:KEQU) and HeartBeam (NASDAQ:BEAT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

Kewaunee Scientific has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, HeartBeam has a beta of -0.76, indicating that its stock price is 176% less volatile than the broader market.

Kewaunee Scientific has higher revenue and earnings than HeartBeam. HeartBeam is trading at a lower price-to-earnings ratio than Kewaunee Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kewaunee Scientific	$282M	0.33	$9.62M	$2.76	11.67
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A

In the previous week, Kewaunee Scientific and Kewaunee Scientific both had 2 articles in the media. Kewaunee Scientific's average media sentiment score of 0.86 beat HeartBeam's score of 0.31 indicating that Kewaunee Scientific is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kewaunee Scientific	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HeartBeam	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kewaunee Scientific has a net margin of 2.97% compared to HeartBeam's net margin of 0.00%. Kewaunee Scientific's return on equity of 11.61% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kewaunee Scientific	2.97%	11.61%	4.82%
HeartBeam	N/A	-686.78%	-348.65%

32.7% of Kewaunee Scientific shares are owned by institutional investors. Comparatively, 7.8% of HeartBeam shares are owned by institutional investors. 14.1% of Kewaunee Scientific shares are owned by insiders. Comparatively, 18.0% of HeartBeam shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

HeartBeam has a consensus price target of $4.00, indicating a potential upside of 895.52%. Given HeartBeam's stronger consensus rating and higher probable upside, analysts clearly believe HeartBeam is more favorable than Kewaunee Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kewaunee Scientific	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
HeartBeam	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Summary

Kewaunee Scientific beats HeartBeam on 9 of the 14 factors compared between the two stocks.

How does HeartBeam compare to Hyperfine?

HeartBeam (NASDAQ:BEAT) and Hyperfine (NASDAQ:HYPR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

HeartBeam has a beta of -0.76, indicating that its share price is 176% less volatile than the broader market. Comparatively, Hyperfine has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

HeartBeam has higher earnings, but lower revenue than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A
Hyperfine	$11.40M	7.92	-$35.57M	-$0.38	N/A

In the previous week, Hyperfine had 9 more articles in the media than HeartBeam. MarketBeat recorded 11 mentions for Hyperfine and 2 mentions for HeartBeam. Hyperfine's average media sentiment score of 0.50 beat HeartBeam's score of 0.31 indicating that Hyperfine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartBeam	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hyperfine	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HeartBeam has a net margin of 0.00% compared to Hyperfine's net margin of -210.75%. Hyperfine's return on equity of -97.88% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-686.78%	-348.65%
Hyperfine	-210.75%	-97.88%	-61.81%

7.8% of HeartBeam shares are held by institutional investors. Comparatively, 15.0% of Hyperfine shares are held by institutional investors. 18.0% of HeartBeam shares are held by insiders. Comparatively, 26.3% of Hyperfine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

HeartBeam presently has a consensus price target of $4.00, suggesting a potential upside of 895.52%. Hyperfine has a consensus price target of $2.03, suggesting a potential upside of 138.79%. Given HeartBeam's stronger consensus rating and higher probable upside, equities analysts plainly believe HeartBeam is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Hyperfine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Hyperfine beats HeartBeam on 9 of the 15 factors compared between the two stocks.

How does HeartBeam compare to electroCore?

HeartBeam (NASDAQ:BEAT) and electroCore (NASDAQ:ECOR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

In the previous week, HeartBeam and HeartBeam both had 2 articles in the media. electroCore's average media sentiment score of 0.60 beat HeartBeam's score of 0.31 indicating that electroCore is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartBeam	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
electroCore	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.8% of HeartBeam shares are held by institutional investors. Comparatively, 26.7% of electroCore shares are held by institutional investors. 18.0% of HeartBeam shares are held by insiders. Comparatively, 7.8% of electroCore shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

electroCore has higher revenue and earnings than HeartBeam. electroCore is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A
electroCore	$32.03M	2.36	-$13.97M	-$1.66	N/A

HeartBeam has a net margin of 0.00% compared to electroCore's net margin of -39.96%. electroCore's return on equity of 0.00% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-686.78%	-348.65%
electroCore	-39.96%	N/A	-81.35%

HeartBeam has a beta of -0.76, suggesting that its stock price is 176% less volatile than the broader market. Comparatively, electroCore has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

HeartBeam currently has a consensus target price of $4.00, indicating a potential upside of 895.52%. electroCore has a consensus target price of $18.00, indicating a potential upside of 114.54%. Given HeartBeam's stronger consensus rating and higher probable upside, analysts plainly believe HeartBeam is more favorable than electroCore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

HeartBeam and electroCore tied by winning 7 of the 14 factors compared between the two stocks.

Get HeartBeam News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BEAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BEAT vs. The Competition

Export

Metric	HeartBeam	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$22.03M	$5.52B	$7.25B	$13.04B
Dividend Yield	N/A	1.75%	2.52%	22.89%
P/E Ratio	-0.77	25.48	275.44	25.51
Price / Sales	N/A	66.54	562.05	79.58
Price / Cash	N/A	32.25	77.16	53.04
Price / Book	6.52	5.81	10.64	6.00
Net Income	-$21.01M	$146.14M	$3.49B	$380.50M
7 Day Performance	-27.99%	-1.66%	-3.21%	-3.35%
1 Month Performance	-3.65%	-4.35%	-7.65%	-6.23%
1 Year Performance	-78.03%	0.80%	2.92%	-3.96%

HeartBeam Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BEAT HeartBeam	1.9995 of 5 stars	$0.39 -4.2%	$4.00 +939.0%	-76.8%	$22.03M	N/A	N/A	1,700
APYX Apyx Medical	3.2494 of 5 stars	$2.55 +0.1%	$6.50 +154.6%	-13.3%	$107.53M	$52.84M	N/A	205
CNXU Conexeu Sciences	2.033 of 5 stars	$3.57 -2.6%	$20.00 +461.0%	N/A	$101.13M	N/A	N/A	4	Gap Up
KEQU Kewaunee Scientific	1.5052 of 5 stars	$34.44 +2.1%	N/A	-22.2%	$99.88M	$282M	12.48	1,231
HYPR Hyperfine	3.0405 of 5 stars	$0.86 -0.7%	$2.03 +135.3%	-57.6%	$92.05M	$16.54M	N/A	102

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BEAT) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HeartBeam (BEAT) Competitors

BEAT vs. APYX, CNXU, KEQU, HYPR, and ECOR

How does HeartBeam compare to Apyx Medical?

Summary

How does HeartBeam compare to Conexeu Sciences?

Summary

How does HeartBeam compare to Kewaunee Scientific?

Summary

How does HeartBeam compare to Hyperfine?

Summary

How does HeartBeam compare to electroCore?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAT vs. The Competition

HeartBeam Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HeartBeam (BEAT) Competitors

BEAT vs. APYX, CNXU, KEQU, HYPR, and ECOR

How does HeartBeam compare to Apyx Medical?

Which has stronger earnings and valuation, APYX or BEAT?

Do analysts prefer APYX or BEAT?

Which has more risk & volatility, APYX or BEAT?

Do insiders and institutionals hold more shares of APYX or BEAT?

Is APYX or BEAT more profitable?

Does the media prefer APYX or BEAT?

Summary

How does HeartBeam compare to Conexeu Sciences?

Do institutionals and insiders hold more shares of CNXU or BEAT?

Do analysts prefer CNXU or BEAT?

Does the media prefer CNXU or BEAT?

Is CNXU or BEAT more profitable?

Which has higher earnings & valuation, CNXU or BEAT?

Summary

How does HeartBeam compare to Kewaunee Scientific?

Which has more risk & volatility, KEQU or BEAT?

Which has higher valuation & earnings, KEQU or BEAT?

Does the media favor KEQU or BEAT?

Is KEQU or BEAT more profitable?

Do insiders & institutionals believe in KEQU or BEAT?

Do analysts recommend KEQU or BEAT?

Summary

How does HeartBeam compare to Hyperfine?

Which has more risk and volatility, BEAT or HYPR?

Which has stronger valuation & earnings, BEAT or HYPR?

Does the media favor BEAT or HYPR?

Is BEAT or HYPR more profitable?

Do insiders and institutionals hold more shares of BEAT or HYPR?

Do analysts recommend BEAT or HYPR?

Summary

How does HeartBeam compare to electroCore?

Does the media refer more to BEAT or ECOR?

Do institutionals & insiders hold more shares of BEAT or ECOR?

Which has preferable earnings & valuation, BEAT or ECOR?

Is BEAT or ECOR more profitable?

Which has more risk and volatility, BEAT or ECOR?

Do analysts prefer BEAT or ECOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAT vs. The Competition

HeartBeam Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools